# Biogen

> Biogen is a VC fund in Weston backing Biotechnology and Health Care. See 30 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Weston, United States
- Total investments: 30
- Last investment: Sep 2025
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/biogen-idec
- Website: https://www.biogen.com/en_us/home.html

Biogen is a VC fund in Weston focused on Biotechnology and Health Care. Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies,and the company generates more than $4 billion in annual revenues.

## Contacts

5 contacts available for Biogen. Shizune tracks 10 team members at Biogen. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biogen-idec?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 23 | 77% |
| Health Care | 14 | 47% |
| Therapeutics | 10 | 33% |
| Medical | 8 | 27% |
| Pharmaceutical | 7 | 23% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 20% |
| Series C | 6 | 20% |
| Series A | 5 | 17% |
| Funding Round | 5 | 17% |
| Series D | 2 | 7% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 23 | 77% |
| Germany | 1 | 3% |
| South Korea | 1 | 3% |
| Switzerland | 1 | 3% |
| The Netherlands | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Kolwyck | Director Manufacturing Science - Raw Materials | 0 | — |
| Deborah Glasser | Associate Director - BG12 HCP Marketing | 0 | — |
| Elodie Cramer | Head of Strategic Sourcing | 0 | — |
| Georgia Mitsi | GM Mental Health & VR solutions | 0 | — |
| Jaren Landen | Early Alzheimer's Disease Head | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neela Therapeutics | Neela Therapeutics is a new pediatric central nervous system (CNS) company focused on advancing transformative therapies for rare neuro-genetic diseases |  | Convertible Note | Sep 18, 2025 |  |
| Autobahn Therapeutics | Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $32.7M | Venture - Series Unknown | Sep 08, 2022 |  |
| Accure Health | Accure Health ("Accure") is a privately held, next-generation precision medicine company. Accure is focused on developing AI-powered solutions that leverage patients' biomarker profiles to enable precision therapies delivered to the right cells for the right patients. Accure’s motto is "Cure through Accuracy". |  | Non-equity Assistance | Jan 01, 2022 |  |
| SAGE Therapeutics | SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and aworld-class team of founders, advisors, investors, scientists and managers. | $650M | Post-IPO Equity | Nov 27, 2020 |  |
| Autobahn Therapeutics | Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $76M | Series B | Jun 11, 2020 |  |
| CAMP4 Therapeutics | CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $15M |  | Jan 13, 2020 |  |
| Samsung Bioepis | Samsung Bioepis Co., Ltd. develops and produces biopharmaceutical and biosimilar products. Samsung Bioepis Co., Ltd. has a strategic collaboration agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2012 and is based in Incheon, | $556.1M |  | Jun 28, 2018 |  |
| Neurimmune Holding | Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs.With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closelyresembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low immunogenicity, resulting in superior risk profiles and excellent efficacy.Neurimmune’s pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways. | $150M |  | Oct 25, 2017 |  |
| Solid Biosciences | Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has anestimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial. | $50M | Series C | Mar 30, 2017 |  |
| Rodin Therapeutics | Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biologycapabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC). | $17.3M | Series B | Jan 06, 2016 |  |

10 of 30 investments shown.

## Co-investors
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 3 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 3 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 3 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Biogen invest in?

Biogen invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Biogen?

Public channels for Biogen include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Biogen?

The team at Biogen includes David Kolwyck (Director Manufacturing Science - Raw Materials), Deborah Glasser (Associate Director - BG12 HCP Marketing) and Elodie Cramer (Head of Strategic Sourcing), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co